Welcome to our dedicated page for Colgate Palmolive Co SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Colgate-Palmolive Company filings document a global consumer-products issuer with NYSE-listed common stock and registered debt securities. The company's 8-K reports cover earnings releases, the Strategic Growth and Productivity Program, reportable operating segment realignments, senior-note activity, debt-listing changes and governance events such as director elections and officer succession.
Proxy materials describe board elections, executive compensation, shareholder voting matters and strategic priorities tied to growth, efficiency and cash flow. The filings also identify registered securities, including common stock and multiple note series, and provide formal records for shareholder meetings, compensation arrangements and changes affecting listed note classes.
Colgate-Palmolive common stock holder plans to sell shares under Rule 144. A holder has filed a notice to sell 20,989 shares of Colgate-Palmolive common stock through Merrill Lynch on or about 02/10/2026, with an indicated aggregate market value of $1,978,210.97 on the NYSE.
The shares were acquired on 02/10/2026 from Colgate-Palmolive via an employee stock option exercise structured as a broker-assisted cashless exercise. Colgate-Palmolive had 806,064,942 shares outstanding at the time referenced, providing context for the relative size of this planned sale.
Colgate-Palmolive Chief Human Resources Officer Sally Massey reported an option exercise and related share sale. On February 5, 2026, she exercised stock options for 15,851 shares of common stock at $76.41 per share, awarded under the company’s incentive compensation plan.
That same day, she sold 15,851 shares of common stock at a weighted average price of $95.0279, with part of the proceeds used to pay the option exercise price and related tax withholding. After these transactions, she directly owned 13,751 shares of Colgate-Palmolive common stock and held an additional 8,111 shares indirectly through the issuer’s 401(k) plan trustee.
Colgate-Palmolive’s Chief Financial Officer, Stanley J. Sutula III, exercised stock options and sold shares in a planned transaction. On February 4, 2026, he exercised 97,843 stock options at an exercise price of $81.78 per share under the company’s incentive compensation plan.
That same day, he sold 97,843 shares of common stock at a weighted average price of $94.2662 per share, with a portion of the proceeds delivered to Colgate-Palmolive to cover the option exercise price and related tax withholding. After these transactions, he directly owned 55,310 common shares and indirectly held 328 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive’s Chief Legal Officer and Secretary, Jennifer Daniels, reported an option exercise and share sale. On February 4, 2026, she exercised stock options for 22,000 shares of common stock at $72.29 per share under the company’s incentive plan, increasing her direct holdings to 98,406 shares.
That same day, she sold 22,000 shares of common stock at a weighted average price of $94.3363 per share in multiple transactions, leaving 76,406 shares held directly. A footnote explains that part of the sale proceeds went to Colgate-Palmolive to cover the option exercise price and related tax withholding. She also holds 1,837 shares indirectly through the issuer’s 401(k) plan trustee.
Colgate-Palmolive Chairman, President & CEO Noel R. Wallace reported a sale of common stock. On February 4, 2026, he sold 45,568 shares of Colgate-Palmolive common stock at a weighted average price of $93.9145 per share, in multiple transactions within a stated price range.
After this sale, Wallace directly owned 293,188 common shares. He also reported indirect ownership of 54,281 shares through the issuer's 401(k) plan trustee, 52,000 shares through a spouse trust, and 335 shares through another trust.
Colgate-Palmolive (CL) has a planned Rule 144 stock sale by a shareholder following an option exercise. The holder intends to sell 22,000 shares of Colgate-Palmolive common stock through Merrill Lynch on or around 02/04/2026 on the NYSE, with an aggregate market value of $2,075,398.18.
The shares were acquired the same day by exercising employee stock options via a broker-assisted cashless exercise. Colgate-Palmolive had 806,064,942 common shares outstanding, providing context for the size of this proposed sale.
Colgate-Palmolive reported a planned sale of 45,568 shares of its common stock under a Rule 144 notice, with an aggregate market value of $4,279,497.44. The shares are to be sold through Merrill Lynch on the NYSE around 02/04/2026.
The securities were acquired through vesting of performance share unit awards from Colgate-Palmolive in February and September 2024, granted as part of the issuer’s equity compensation plan.
Colgate-Palmolive common stock is being prepared for sale under Rule 144 following an option exercise. A holder plans to sell 97,843 shares of Colgate-Palmolive common stock through Merrill Lynch on the NYSE, with an aggregate market value of $9,223,283.80.
The shares were acquired on 02/04/2026 via an exercise of employee stock options in a broker-assisted cashless transaction, with payment made the same day. Colgate-Palmolive had 806,064,942 shares of common stock outstanding, providing context for the size of this planned sale under Rule 144.
Colgate-Palmolive Company filed a current report to furnish a press release announcing its earnings for the quarter and year ended December 31, 2025. The press release, dated January 30, 2026, is attached as Exhibit 99 and provides the company’s detailed financial results.
The earnings information is provided under Item 2.02 as furnished, not filed, which limits its use under certain securities law provisions. The filing also includes an Inline XBRL cover page data file as Exhibit 104.
Colgate-Palmolive Company director reports stock acquisition under compensation plan
A director of Colgate-Palmolive Company reported acquiring 238 shares of common stock on 01/02/2026 at a price of $78.66 per share. The filing notes this represents a portion of the director’s annual cash retainer that was deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors.
Following this transaction, the director beneficially owns 5,313 shares of Colgate-Palmolive common stock directly and 36 shares indirectly through a family trust.